Travel Grant 2024, Korea, BIOKOREA, 8-10 maj 2024
| Reference number | |
| Coordinator | SVF Vaccines AB |
| Funding from Vinnova | SEK 25 000 |
| Project duration | May 2024 - May 2024 |
| Status | Completed |
| Venture | Global cooperation 2024 |
Important results from the project
BioKorea 2024 Objectives: 1. Identify Korean VCs to invest in SVF Vaccines: Not fulfilled 2. Identify Korean corporate partner for SVF-001: Fulfilled - one Korean company has expressed an interest in the partnering the SVF-001 project 3. Continue discussions with Korean CDMOs. Fulfilled. One site visit to a Korean CDMO was made and a face-to-face meeting was held with senior staff from a second Korean CDMO.
Expected long term effects
Objective 2. Partnership discussions are expected to start within several weeks with the potential Korean collaborator. Objective 3: Contract discussions will now be initiated with the preferred Korean CDMO following the successful on-site meetings at their manufacturing facility
Approach and implementation
Objective 2: Implementation will be initiated through conceptual discussions regarding the collaboration, followed by term sheet exchanges and concluded with a final legal agreement. Objective 3: Further technical meetings will be held in parallel with contract discussions